Literature DB >> 2825981

Synergistic effects of recombinant human tumor necrosis factor and hyperthermia on in vitro cytotoxicity and artificial metastasis.

Y Niitsu1, N Watanabe, H Umeno, H Sone, H Neda, N Yamauchi, M Maeda, I Urushizaki.   

Abstract

Synergy in cytotoxic effect between recombinant human tumor necrosis factor and hyperthermia (incubation at 38.5 degrees C or 40 degrees C) was observed to occur against L-M (mouse tumorigenic fibroblast) cells and shown to be related to an accelerated turnover rate of recombinant human tumor necrosis factor-receptor complex under elevated temperatures rather than to changes in number of cell receptors or binding strength. However, no synergy in cytotoxic effect was observed to occur against human embryonic lung (HEL) cells. A clearly synergistic inhibition of metastatic tumor growth by combined administration of recombinant human tumor necrosis factor (300 units) and whole-body hyperthermia (40 degrees C, 30 min) was also observed in BALB/c mice previously given injections of 1 x 10(6) Meth-A (MH) cells/mouse via tail vein, neither of which alone resulted in significant inhibition.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2825981

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Successful treatment of a case of hepatocellular carcinoma with tumor necrosis factor and local hyperthermia.

Authors:  M Maeda; N Watanabe; N Yamauchi; Y Tsuji; Y Niitsu
Journal:  Gastroenterol Jpn       Date:  1991-12

2.  In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion.

Authors:  D Liénard; F J Lejeune; P Ewalenko
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

Review 3.  Hyperthermic modulation of macrophage-tumor cell interactions.

Authors:  S P Tomasovic; J Klostergaard
Journal:  Cancer Metastasis Rev       Date:  1989-12       Impact factor: 9.264

4.  Characterization of tumor-necrosis-factor-gene-transduced tumor-infiltrating lymphocytes from ascitic fluid of cancer patients: analysis of cytolytic activity, growth rate, adhesion molecule expression and cytokine production.

Authors:  Y Itoh; Y Koshita; M Takahashi; N Watanabe; Y Kohgo; Y Niitsu
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

5.  Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats.

Authors:  J H de Wilt; E R Manusama; S T van Tiel; M G van Ijken; T L ten Hagen; A M Eggermont
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

6.  Enhancement of lysosomal enzyme activity by recombinant human tumor necrosis factor and its role in tumor cell killing in vitro.

Authors:  N Watanabe; N Yamauchi; H Neda; M Maeda; Y Tsuji; T Okamoto; S Akiyama; H Sasaki; N Tsuji; Y Niitsu
Journal:  Jpn J Cancer Res       Date:  1992-06

7.  Reversal of tumor necrosis factor resistance in tumor cells by adriamycin via suppression of intracellular resistance factors.

Authors:  N Watanabe; T Okamoto; N Tsuji; H Sasaki; S Akiyama; D Kobayashi; T Sato; N Yamauchi; Y Niitsu
Journal:  Jpn J Cancer Res       Date:  1995-04

8.  Platelet aggregation induced by adenosine diphosphate released from cloned murine fibrosarcoma cells is positively correlated with the experimental metastatic potential of the cells.

Authors:  Y Mogi; K Kogawa; T Takayama; N Yoshizaki; K Bannai; H Muramatsu; K Koike; Y Kohgo; N Watanabe; Y Niitsu
Journal:  Jpn J Cancer Res       Date:  1991-02

9.  Lysosome labilizers potentiate the antitumor effects of tumor necrosis factor-alpha.

Authors:  T Masegi; A Kato; K Kitai; M Fukuoka; K Soma; Y Ichikawa; S Nakamura; N Watanabe; Y Niitsu
Journal:  Jpn J Cancer Res       Date:  1993-04

10.  Hyperthermic enhancement of the antitumor effect of natural human tumor necrosis factor-alpha and -beta: an in vitro and in vivo study.

Authors:  T Maeda; S Fuchimoto; K Orita
Journal:  Jpn J Cancer Res       Date:  1988-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.